This randomized pilot phase I trial studies the side effects of donor bone marrow derived mesenchymal stem cells in controlling heart failure in patients with cardiomyopathy caused by anthracyclines. Donor bone marrow derived mesenchymal stem cells may help to control symptoms of heart failure and improve heart function.
Patients with LVEF </= 40% documented from treatment with anthracyclines for any malignancy at any dose at any time without evidence of other causes of cardiomyopathy.
Age >/= 18 and </= 90 years of age. English and non-English speaking patients are eligible.
Documented NYHA class I, II and III.
For patients who have received trastuzumab: Persistent LV dysfunction must be present 90 days after discontinuation of trastuzumab.
Evidence of Ischemic Heart Disease as determined by study cardiologist.
Significant Valvular Disease. (AS with AVA <1.5 and severe AR and MR)
History of Familial Cardiomyopathy.
Recent documented myocarditis within 2 months of enrollment.
M.D. Anderson Cancer Center
Lead sponsor
National Cancer Institute (NCI)
Collaborator